**Core tip:** Obtaining an adequate peripheral blood stem cell yield is essential for the successful outcome of autologous hematopoietic stem cell transplant in multiple myeloma. While growth factor mobilization continues to be largely successful, suboptimal collection rates have been noted, particularly as use of novel therapies continue to increase. Chemomobilization remains toxic and has not been associated with better disease control. The newest mobilizing agent, plerixafor, is capable of overcoming suboptimal mobilization even in patients who are at a high risk of mobilization failure. Each mobilization strategy should be selected based on patient specific variables as well as risk factors for mobilization failure.

INTRODUCTION
============

High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant (auto-HCT) is considered standard of care for eligible patients with multiple myeloma (MM). MM remains the most common indication for auto-HCT, accounting for over 6000 transplants in the United States alone in 2013\[[@B1]\]. Auto-HCT has been shown to prolong progression-free survival and overall survival in patients with MM\[[@B2]-[@B4]\], a benefit that has been maintained even after the availability of immunomodulatory drugs such as thalidomide and lenalidomide\[[@B5],[@B6]\], and proteasome inhibitors like bortezomib. Mobilization and collection of an optimal number of HSC is a fundamental requirement for auto-HCT. The optimal collection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available mobilization strategies include growth factors alone, growth factors in combination with chemotherapy, or growth factors in combination with chemokine receptor antagonists; however, the optimal strategy has yet to be elucidated. Herein, we review the data surrounding each approach.

SOURCE OF HSCs
==============

Historically, bone marrow (BM) was used as the sole source of HSC for transplantation\[[@B7],[@B8]\]. However, the ability to mobilize HSC to peripheral blood (PB) has eliminated the risk of general anesthesia, intubation, and painful aspirations associated with BM harvesting. Peripheral blood stem cell (PBSC) collection can be performed in the outpatient setting with a shorter recovery time. Additionally, use of PBSC reduces time to hematopoietic reconstitution, hospital stay, and need for transfusions\[[@B9]-[@B11]\]. Consequently, PB has largely replaced BM as the source of HSC for auto-HCT\[[@B12]\].

PBSC DOSE
=========

The number of CD34 expressing mononuclear cells in PBSC collection correlates well with engraftment kinetics and thus is used as a surrogate marker of HSC\[[@B13]-[@B16]\] (Figure [1](#F1){ref-type="fig"}). A dose of \> 2 million CD34^+^ cells per kilogram (cells/kg) is considered the minimum acceptable dose for timely engraftment\[[@B17]\]. However, larger cell doses have been associated with a more rapid time to platelet and neutrophil recovery\[[@B18],[@B19]\] and therefore ≥ 3-5 million CD34 cells/kg is considered an optimal target\[[@B20],[@B21]\].

![Correlation of harvested CD34^+^ cells counts with white blood cell count and peripheral blood CD34^+^ cell count. A: Correlation of harvested CD34^+^ cells counts with white blood cell count; B: Correlation of harvested CD34^+^ cells counts with peripheral blood CD34^+^ cell count. Reprinted by permission from Macmillan Publishers Ltd: *Bone Marrow Transplant* 1997\[[@B16]\]. <http://www.nature.com/bmt/index.html>.](WJT-7-250-g001){#F1}

PBSC MOBILIZATION APPROACHES
============================

HSC primarily reside in the BM and account for 1%-4% of all mononuclear cells\[[@B13],[@B15],[@B22]\]. Retention of HSC in the BM is dependent on interactions between cell adhesion molecules on the surface of HSC, such as chemokine receptor 4 and very late antigen 4 (VLA4), and BM stromal factors, such as vascular cell adhesion molecule (VCAM-1) and stromal cell-derived factor-1 (SDF-1)\[[@B23]\]. Mobilization of HSC from BM to PB is the result of induced chemical disruption of these interactions between HSC and BM stroma. Cytokines, such as granulocyte-colony stimulating factor (G-CSF), and chemotherapy drugs like cyclophosphamide play an important role in releasing HSC from their niches in the BM\[[@B23]-[@B25]\] (Figure [2](#F2){ref-type="fig"}).

![Bone marrow microenvironment (A) at physiologic state and effects of (B) granulocyte colony stimulating factor mobilization and (C) Plerixafor mobilization. Reprinted from *Journal of Cellular Biochemistry*, Vol 99/edition 3, Bruno Nervi, Dan C. Link, John F DiPersio, Cytokines and Hematopoietic Stem Cell Mobilization, 690-705, 2010, with permission from Wiley\[[@B26]\]. G-CSF: Granulocyte colony stimulating factor; HSC: Hematopoietic stem cell; SDF-1: Stromal cell-derived factor-1; VCAM-1: Vascular cell adhesion molecule.](WJT-7-250-g002){#F2}

Growth factors alone
--------------------

Historically, growth factors alone have been largely successful in mobilizing an adequate cell yield in MM patients undergoing auto-HCT\[[@B26],[@B27]\] (Table [1](#T1){ref-type="table"}). G-CSF has well established kinetics as well as favorable toxicity and cost profiles\[[@B28]-[@B30]\] but has been associated with suboptimal mobilization in over 20% of MM patients\[[@B31]-[@B33]\]. Data regarding a dose-response relationship between G-CSF and CD34^+^ cell yield is discordant but doses up to 40 μg per kilogram per day (μg/kg per day) have been studied\[[@B34]-[@B36]\]. A widely accepted G-CSF dose for PBSC mobilization is 10 μg/kg per day as single or divided doses.

###### 

Growth factor mobilization

  **Ref**.                   **Disease**                 **Collection strategy**      ***n***               **CD34^+^ yield (× 10^-6^ cell/kg): Median (range)**   **Failure *n* (%)**
  -------------------------- --------------------------- ---------------------------- --------------------- ------------------------------------------------------ ---------------------
  Desikan et al\[[@B26]\]    MM                          G-CSF 10-16 μg/kg per day    117                   6.2 (0.6-34.1)                                         NR
  Kröger et al\[[@B27]\]     MM                          G-CSF 10-24 μg/kg per day    25                    3.8 (0.3-17)                                           3 (12)
  Popat et al\[[@B31]\]      MM                          G-CSF                        302                   NR                                                     9%
  Pusic et al\[[@B90]\]      MM                          G-CSF 10 μg/kg per day       384                   4.6                                                    24 (6.3)
  NHL HD                     G + C                       17                           8.5                   1 (5.9)                                                
  Weaver et al\[[@B34]\]     BC                          G-CSF 10 μg/kg per day       14                    0.6 (0.1-2.8)                                          NR
                             G-CSF 20 μg/kg per day      13                           1 (0.2-5.2)                                                                  
                             G-CSF 30 μg/kg per day      14                           2.4 (0.6-6.8)                                                                
                             G-CSF 40 μg/kg per day      14                           1.4 (0.1-4.8)                                                                
  Weisdorf et al\[[@B42]\]   NHL                         GM-CSF 250 μg/m^2^ per day   16                    4.78 (3.02-10.68)                                      0
  HD                         G-CSF 250 μg/m^2^ per day   15                           8.01 (3.17-29)        0                                                      
  Spitzer *et* \[[@B41]\]    BC GCT                      GCSF 10 mcg/kg per day       26                    21.45 (1.63-182.91)                                    NR
  NHL HD                     GCSF 10 mcg/kg per day +    24                           13.33 (0.56-102.08)                                                          
  MM                         GM-CSF 5 mcg/kg per day                                                                                                               
  Hosing et al\[[@B39]\]     MM                          PEG 12 mg × 1                19                    8.4 (4.1-15.8)                                         0
                             G-CSF 10 μg/kg per day      8                            8.1 (5.17-19.2)       0                                                      

MM: Multiple myeloma; G-CSF: Granulocyte colony stimulating factor; NR: Not reported; BC: Breast cancer; NHL: Non-hodgkin's lymphoma; GM-CSF: Granulocyte macrophage colony stimulating factor; HD: Hodgkin's disease; GCT: Germ cell tumor; PEG: Pegylated filgrastim.

Other growth factors such as granulocyte-macrophage- colony stimulating factor (GM-CSF), pegylated G-CSF, and tbo G-CSF have also been studied for PBSC mobilization in MM patients\[[@B37]-[@B42]\]. When G-CSF was compared to GM-CSF in MM patients, CD34^+^ cell yield was similar between the two groups, but GM-CSF-mobilized patients had a longer duration of neutropenia\[[@B43]\]. *In-vitro* data suggest that combination of G-CSF + GM-CSF may improve PBSC yield\[[@B44],[@B45]\], but clinical trial data has not found a significant difference in CD34^+^ cell yield or time to hematopoietic recovery with combination therapy\[[@B41]\].

Pegylated (PEG) filgrastim, a covalent conjugate of G-CSF and monomethoxy-polyethylene glycol, has a terminal half-life of 15-80 h, which enables less frequent administration compared to G-CSF. Given as a single 12 mg injection followed by PBSC collection, all MM patients who received PEG filgrastim successfully collected their target CD34^+^ cells/kg dose\[[@B39]\]. Similarly, a multi-dose regimen of PEG filgrastim had a higher CD34^+^ cells yield on first apheresis compared to G-CSF, but no differences in overall cell yield was observed\[[@B46]\]. Its convenient dosing schedule makes it an attractive option for PBSC mobilization.

Tbo-filgrastim is a non-glycosylated recombinant methionyl human G-CSF manufactured using the bacterium strain *E. coli* K802\[[@B47]\]. While not FDA approved for stem cell mobilization, retrospective data in MM patients found no difference in overall cell yield, number of apheresis sessions required for collection, nor need for rescue therapy with plerixafor\[[@B38],[@B48]\].

Myelosuppressive chemotherapy
-----------------------------

Transient circulation of PBSC occurs during the recovery phase of chemotherapy-induced pancytopenia\[[@B22],[@B49],[@B50]\] and is augmented by growth factor support\[[@B22]\] (Table [2](#T2){ref-type="table"}). This process, chemomobilization (CM), provides not only higher cell yields than G-CSF alone, but also affords anti-myeloma activity\[[@B32],[@B51]-[@B54]\]. Cyclophosphamide (CY) 2-4 g/m^2^, either alone or in combination with other chemotherapeutic agents, is commonly used in CM and has been a successful mobilization technique even in patients who underwent induction therapy with novel agents\[[@B31],[@B55]-[@B59]\]. The impact of increased doses of CY on PBSC yields has shown conflicting results but was consistently associated with a longer duration of neutropenia as well as the use of antibiotics and blood products\[[@B54],[@B60]-[@B64]\]. No additional impact on cell yield or objective response rate has been seen with the use of combination chemotherapy followed by growth factor\[[@B55],[@B65]\] (Table [3](#T3){ref-type="table"}). Furthermore, despite the potential benefit of cytoreduction, CM has not been associated with a better disease control or survival in MM\[[@B32],[@B51],[@B52],[@B66]-[@B68]\].

###### 

Growth factors following chemotherapy

  **Ref**.                                  **Disease**   **Collection strategy**     ***n***   **CD34^+^ yield (× 10^-6^ cell/kg): Median (range)**   **Failure rates *n* (%)**
  ----------------------------------------- ------------- --------------------------- --------- ------------------------------------------------------ ---------------------------
  Weaver et al\[[@B91]\]                    MM ML BC      G-CSF 6 μg/kg per day       49        12 (0.1-54)                                            2 (4.1)
  GM-CSF 250 μg/m^2^ per day                49            5.4 (0.02-64)               4 (8.2)                                                          
  GM-CSF × 5 d then G-CSF 6 μg/kg per day   52            10.5 (0.4-96)               1 (1.9)                                                          
  Arora et al\[[@B43]\]                     MM            G-CSF 250 μg/m^2^ per day   35        16.4 (1.1-71.7)                                        NR
  GM-CSF 250 μg/m^2^ per day                37            12.8 (0.4-94.5)                                                                              
  Tricot et al\[[@B46]\]                    MM            PEG 6 mg q7d × 2            97        NR; no difference                                      NR
  G-CSF 10 μg/kg per day                    140                                                                                                        
  Fruehauf et al\[[@B92]\]                  MM            PEG 12 mg × 1               26        9.7 (4.9-40.5)                                         3 (11.5)
  Steidl et al\[[@B93]\]                    MM            PEG 12 mg × 1               12        7.4 (4.9-38)                                           0
  G-CSF 8.5 μg/kg per day                   12            10.8 (5-87)                 0                                                                

MM: Multiple myeloma; ML: Malignant lymphoma; BC: Breast cancer; G-CSF: Granulocyte colony stimulating factor; GM-CSF: Granulocyte macrophage colony stimulating factor; NR: Not reported; NHL: Non-hodgkin's lymphoma; PEG: Pegylated filgrastim.

###### 

Impact of chemotherapy on cell yield and morbidity

  **Ref.**                        **Collection strategy**                   ***n***            **CD34^+^ yield (× 10^-6^ cell/kg): median (range)**   **Hospital days: median (range)**   **Infection (%)**   **Transfusions (%) platelet/PRBC**
  ------------------------------- ----------------------------------------- ------------------ ------------------------------------------------------ ----------------------------------- ------------------- ------------------------------------
  Desikan *et al*\[[@B32]\]       CY 6 g/m^2^ + G-CSF 6 μg/kg per day       22                 33.4 (NR)                                              No difference                       18                  86/86
                                  G-CSF 16 μg/kg per day                    22                 5.8 (NR)                                                                                   0                   18/55
  Alegre *et al*\[[@B51]\]        CY 4 g/m^2^ + GM-CSF                      18                 6.8 (1.8-34.8)                                         21 (16-34)                          11                  33.3/27.7
                                  G-CSF 10 μg/kg per day                    22                 4.85 (2.1-10.05)                                       0                                   0                   0/0
  Fitoussi *et al*\[[@B60]\]      CY 7 g/m^2^ + HGF                         74                 8.6 (0.4-166)                                          15 (9-34)                           17.6                75.7/94.6
                                  CY 4 g/m^2^ + HGF                         42                 13.4 (0.7-66.8)                                        22 (13-55)                          16.7                26.2/52.4
  Jantunen *et al*\[[@B61]\]      CY 4 g/m^2^ + G-CSF 5-10 μg/kg per day    32                 4.9 (0.8-47.4)^1^                                      9 (6-14)                            NR                  34/53
                                  CY 1.2-2 g/m^2^ + G-CSF 5 μg/kg per day   42                 5.6 (0.9-19)^1^                                        5 (3-12)                            NR                  0/28
  Gojo *et al*\[[@B65]\]          CY 4.5 g/m^2^ + G-CSF                     28                 21.38 (0-106.8)                                        8 (4-24)                            25                  57/NR
  CY 4.5 g/m^2^ + VP-16 + G-CSF   49                                        22.39 (0-114.71)   7 (3-68)                                               53                                  67/NR               
  Hamadani *et al*\[[@B94]\]      CY 3-4 g/m^2^ + G-CSF                     55                 16.6 (2-82)                                            4 (1-9)                             NR                  21.8/34.5
  CY 1.5 g/m^2^ + G-CSF           68                                        7.5 (0-18)         3 (1-5)                                                NR                                  2.9/8.8             
  Hiwase *et al*\[[@B95]\]        CY 3-4 g/m^2^ + G-CSF                     26                 7.71                                                   7 (3-22)                            19                  No difference
  CY 1-2 2 g/m^2^ + G-CSF         61                                        5.17               6 (3-18)                                               5                                                       

^1^1st apheresis session. PRBC: Packed red blood cells; CY: Cyclophosphamide; G-CSF: Granulocyte colony stimulating factor; NR: Not reported; HGF: Hematopoietic growth factor; VP-16: Etoposide.

Chemokine receptor antagonist
-----------------------------

The newest mobilizing agent, plerixafor, rapidly and reversibly inhibits chemokine receptor CXCR4 on HSC, thereby preventing the binding of SDF-1a to CXCR4. Synergistic effect on PBSC mobilization is observed when plerixafor is given in combination with G-CSF\[[@B69],[@B70]\]. A phase III randomized, placebo controlled trial in MM patients compared mobilization with plerixafor + G-CSF to placebo + G-CSF. Use of plerixafor resulted in an increase in proportion of patients that were able to collect a cell yield of ≥ 6 × 10^6^/kg with fewer apheresis procedures compared to the G-CSF only group. Transplant outcomes were similar between groups\[[@B71]\]. Plerixafor can overcome suboptimal mobilization seen with prolonged prior lenalidomide therapy and other conventional chemotherapy agents\[[@B72],[@B73]\]. Following failed attempts to mobilize, MM patients received a combination of G-CSF and plerixafor. In this population, at least 70% of patients were able to achieve a sufficient PBSC yield, without any evidence of tumor mobilization\[[@B73],[@B74]\]. Plerixafor is successful when used as the initial mobilization strategy but at an increased drug acquisition cost and in patients that presumably could have attained an appropriate cell yield with G-CSF alone\[[@B75],[@B76]\].

Risk adaptive strategies use initial mobilization with G-CSF alone and utilize plerixafor only in patients whose PB CD34^+^ count on day 4 is less than a predetermined threshold (10 × 10^6^/L-10 × 10^9^/L). Such strategies are associated with fewer mobilization failures when compared to traditional mobilization methods and appear to be cost effective\[[@B76]-[@B79]\]. Additional methods of cost reduction, namely the use of tbo-filgrastim, in combination with plerixafor has been studied. Prospective data in MM patients found similar overall cell yields without any mobilization failures\[[@B80]\].

PREDICTORS OF SUBOPTIMAL MOBILIZATION
=====================================

Mobilization failure is generally defined as the inability to procure 2 × 10^6^ CD34^+^ cells/kg in 4 apheresis sessions. Despite recent advances in PBSC collection strategies, failure to obtain an adequate cell dose continues to delay and preclude auto-HCT in otherwise suitable transplant candidates. Factors associated with inadequate HSC mobilization in MM patients include: Thrombocytopenia\[[@B81]\], age \> 60 years\[[@B36],[@B58],[@B82]\], extensive treatment course\[[@B17]\], prior radiotherapy, prior exposure to alkylating agents\[[@B17],[@B83]\], and prolonged use of lenalidomide\[[@B20],[@B21],[@B31],[@B84],[@B85]\]. Such factors have been incorporated in consensus guidelines on stem cell mobilization (Table [4](#T4){ref-type="table"}).

###### 

International Myeloma Working Group Consensus guidelines and recommendations on mobilization in malignant lymphoma\[[@B20]\]

  **Strategy**                          **Recommendations**
  ------------------------------------- ------------------------------------------------------------------------
  Mobilization                          
  G-CSF alone                           Limit use to patients
  Treated with ≤ 1 line of therapy      
  Never exposed to melphalan            
  Received ≤ 4 cycles of lenalidomide   
  Use doses from 10-16 μg/kg per day    
  Monitor PB CD34^+^ count              
  Chemomobilization + G-CSF             Limit to patients who have not adequately responded to salvage therapy
  Plerixafor                            Suitable for all patients particularly if goals include
  Highest cell yield obtainable         
  Fewer apheresis sessions              
  Remobilization                        
  Plerixafor                            P + G-CSF or P + CM + G-CSF
  Chemomobilization                     Acceptable in patients who failed cytokine mobilization
  Bone marrow harvest                   Use as third-line option in patients in whom ASCT is compelling

PBCD34^+^: Peripheral blood CD34^+^ cells; P + G-CSF: Plerixafor + granulocyte colony stimulating factor; P + CM + G-CSF: Plerixafor + chemomobilization + granulocyte colony stimulating factor.

Lenalidomide's impact on cell yield is of particular concern due to its common use in frontline therapy\[[@B86]\]. While known to cause neutropenia and thrombocytopenia, the exact mechanism of lenalidomide induced myelosuppression is not fully known. In one study, lenalidomide was associated with a significant decrease in expression of transcription factor PU. 1, which is critical for myeloid maturation\[[@B87]\]. In another study, lenalidomide-treated patients were found to have decreased BM CD34^+^ cells after six cycles of therapy\[[@B88]\]. This supports the literature that identifies lenalidomide as a risk factor for suboptimal stem cell collection and suggests that transplant eligible patients receiving lenalidomide should proceed to mobilization as early as feasible.

Despite identification of risk factors for poor mobilization, predictive algorithms have not correctly identified poor mobilizers\[[@B89]\]. The best predictor of adequate CD34^+^ cell collection is the pre-collection PB CD34^+^ cell count. A strong correlation exists with PB CD34^+^ cell count and the final CD34^+^ cell collection (Figure [1](#F1){ref-type="fig"}). PB CD34^+^ count ≥ 20 × 10^3^ CD34^+^ cells/mL was associated with an adequate HSC collection in 94% of patients\[[@B16],[@B90]\].

CONCLUSION
==========

In summary, obtaining an adequate PBSC yield is essential for the successful outcome of auto-HCT in MM. Each mobilization strategy reviewed here has its own advantages and disadvantages (Table [5](#T5){ref-type="table"}) and should be selected based on patient specific variables. Current practice at the authors' institution is detailed in Figure [3](#F3){ref-type="fig"}; however, practitioners should be cognizant of risk factors for mobilization failure and utilize appropriate algorithms to optimize stem cell collection.

![Mobilization strategies at authors' institution. CM: Chemomobilization; G-CSF: Granulocyte colony stimulating factor.](WJT-7-250-g003){#F3}

###### 

Advantages and disadvantages of mobilization strategies

  **Mobilization strategy**                  **Advantages**                        **Disadvantages**
  ------------------------------------------ ------------------------------------- ------------------------
  Growth factor                              Cost effective                        No anti-myeloma effect
  Successful mobilization in most patients   Multiple injections and collections   
  Predictable schedule                       Potential sub-optimal yield           
  CM                                         Anti-myeloma effect                   Cytopenias
  Increased cell yield                       Infection risk                        
  Fewer apheresis sessions                   Hospital admission                    
                                             Potential transfusion requirement     
                                             Unpredictable count recovery          
  Plerixafor                                 Rapid kinetics                        Higher drug cost
  Increased cell yield                                                             
  Fewer apheresis sessions                                                         

CM: Chemomobilization.
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